[Relationship between expression of multidrug-resistant genes in nasopharyngeal carcinoma tissue and sensitivity to chemotherapy].
OBJECTIVE
To study the relationship between multidrug-resistant (MDR) expression in nasopharyngeal carcinoma (NPC) and its sensitivity to chemotherapy.


METHODS
The specimens of 23 NPC cases were studied by immunohistochemistry with monoclonal antibody of P-glycoprotein (P-gp), multidrug resistance relation protein (MRP), lung-resistance related protein (LRP), topoisomerase II (Topo II), thymidylate synthase (TS), glutathione-S-transferase (GST-pi). Among them, 20 specimens were taken from primary NPC lesion which were treated with two course of cisplatin (DDP) and 5-fluorouracil (5-FU), 3 specimens were taken from cervical lymph-node of recurrent NPC patients who were treated by radical dissection.


RESULTS
Various MDR parameters were expressed differently in 22 cases except for 1 clear cell carcinoma case. The difference was statistically significant (P < 0.05). However, there were no significant difference of MDR expression either among various carcinoma pathomorphology cell groups or among different clinical stage groups. Expression of LRP and TS were found in 10 and 14 cases respectively and the chemotherapy responders rates were 20% (2/10) and 28.5% (4/14) respectively. While the chemotherapy responders rates were 70% (7/10) and 5/6 in cases without expression. There was significant difference (P < 0.001, and P < 0.05).


CONCLUSIONS
The NPC patients with LRP and TS expression may be less sensitive to chemotherapy with DDP + 5-FU.
Tao
Zhong-qiang
ZQ
Department of Otorhinolaryngology, People's Hospital of Guagxin Autonomous Region, Nanning 530021, China. dzx700902@sina.com
Liu
Shi-cai
SC
Si
Yong-feng
YF
Zhang
Zheng
Z
Zhou
Xiang-zhen
XZ
Deng
Zhuo-xia
ZX
Zhou
Ri-jing
RJ
Huang
Bo
B
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics; D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000494:pharmacology / Q000627:therapeutic use; D018432:Drug Resistance, Multiple / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D004354:Drug Screening Assays, Antitumor; D005260:Female; D005472:Fluorouracil / Q000494:pharmacology / Q000627:therapeutic use; D051549:Glutathione S-Transferase pi / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000235:genetics; D013940:Thymidylate Synthase / Q000235:genetics; D020394:Vault Ribonucleoprotein Particles / Q000235:genetics; D000099187:Major Vault Protein
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D002945:Cisplatin; D005472:Fluorouracil; D051549:Glutathione S-Transferase pi; D013940:Thymidylate Synthase; D020394:Vault Ribonucleoprotein Particles; D000099187:Major Vault Protein